NDC 0173-0904

Nucala

Mepolizumab

Nucala is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Glaxosmithkline Llc. The primary component is Mepolizumab.

• Product ID: 0173-0904_52382938-6de3-4c13-81d0-774c4d9c078b
• NDC: 0173-0904
• Product Type: Human Prescription Drug
• Proprietary Name: Nucala
• Generic Name: Mepolizumab
• Dosage Form: Injection, Solution
• Route of Administration: SUBCUTANEOUS
• Marketing Start Date: 2022-01-22
• Marketing Category: BLA /
• Application Number: BLA761122
• Labeler Name: GlaxoSmithKline LLC
• Substance Name: MEPOLIZUMAB
• Active Ingredient Strength: 40 mg/.4mL
• Pharm Classes: Interleukin-5 Antagonist [EPC], Interleukin-5 Antagonists [MoA]
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 0173-0904-42

1 SYRINGE in 1 CARTON (0173-0904-42) > .4 mL in 1 SYRINGE

• Marketing Start Date: 2022-01-22
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "Nucala" or generic name "Mepolizumab"

NDC	Brand Name	Generic Name
0173-0881	Nucala	mepolizumab
0173-0892	Nucala	mepolizumab
0173-0904	Nucala	mepolizumab